Logo


Maylan gets favourable ruling on one more patent of Copaxone

The company, which is Natco Pharma's marketing partner, hopes to translate this potential para-4 filing into a product launch after clearing legal hurdles

Natco Pharma's formulations facility in Kothur
Natco Pharma's formulations facility in Kothur

NatcoPharmaLimitedonFridayannouncedthattheUSPatentandTrademarkOfficehasruledinfavourofitsmarketingpartnerMylaninitsnewtrialproceedingsovertheclaimsofathirdpatentofmultiplesclerosesdrugCopaxone40mg/mlandfoundtheclaimsunpatentable. OnAugust24,theUSPatentOfficeruledinfavourofMylanonclaimsoftwopatentsofblockbusterdrugCopaxone. Thecompanyhopestotranslatethispotentialpara-4filingintothelaunchafterclearingthelegalhurdlesonebyone.IsraeligenericpharmaceuticalmajorTevaownsthedrug. Ithadlaunched ...